АНТИБАКТЕРИАЛЬНАЯ ТЕРАПИЯ ИНФЕКЦИЙ ДЫХАТЕЛЬНЫХ ПУТЕЙ С ПОЗИЦИИ КОМПЛЕНТНОСТИ ПАЦИЕНТОВ


Цитировать

Полный текст

Аннотация

Рассматривается проблема комплаенса (приверженности лечению) при антибактериальной терапии респираторных инфекций. Подчеркивается, что высокая комплаентность лечения существенно повышает его эффективность. Представлены методы оценки комплаентности, обсуждаются основные ошибки, связанные с несоблюдением режима антибактериальной терапии, и факторы, влияющие на комплаенс. Описываются методы улучшения комплаентности при проведении антибактериальной терапии (уменьшение кратности приема антибиотика, короткие курсы, удобная форма выпуска препарата и т. д.).

Об авторах

А И Синопальников

Государственный институт усовершенствования врачей МО РФ, Москва

Государственный институт усовершенствования врачей МО РФ, Москва

А А Зайцев

Государственный институт усовершенствования врачей МО РФ, Москва

Государственный институт усовершенствования врачей МО РФ, Москва

A I Sinopalnikov

A A Zaitcev

Список литературы

  1. Pechere JC, Hughes D, Kardas P, et al. Non compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents 2007;29:245-53.
  2. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. Antimicrob Chemother 2002;49:897-903.
  3. Insull WJ. The problem of compliance to cholesterol altering therapy. Int Med 1997;241(4):317-25.
  4. Wandstrat T, Kaplan B. Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of acute otitis media. Pediatric Inf Dis J 1997;16:27-29.
  5. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch of Int Med 1993;153:1863-68.
  6. Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconom 1999;15(3):217-28.
  7. Granger B <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Granger%20BB%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Swedberg K <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Swedberg%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Ekman I, et al. CHARM investigators <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22CHARM%20investigators%22%5BCorporate%20Author%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet <javascript:AL_get(this,%20'jour',%20'Lancet.');> 2005;10;366(9502):2005-11.
  8. Daschner F, Marget W. Treatment of recurrent urinary tract infection in children. II. Compliance of parents and children with antibiotic therapy regimen. Acta Paediatr Scand 1975;64(1):105-08.
  9. Charney E, Bynum R, Eldredge D, et al. How well do patients take oral penicillin? A collaborative study in private practice. Pediatr 1967;40:188-95.
  10. Cockburn J, Reid AL, Bowman J, et al. Effects of intervention on antibiotic compliance in patients in general practice. Med J Australia 1987;147:324-28.
  11. Venuta A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Venuta%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Laudizi L <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Laudizi%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Beverelli A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Beverelli%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. J Int Med Res <javascript:AL_get(this,%20'jour',%20'J%20Int%20Med%20Res.');> 1998;26(3):152-58.
  12. Drehobl MA <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Drehobl%20MA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, De Salvo MC <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22De%20Salvo%20MC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Lewis DE <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lewis%20DE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest <javascript:AL_get(this,%20'jour',%20'Chest.');> 2005;128(4):2230-07.
  13. Agarwal G <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Agarwal%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Awasthi S <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Awasthi%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Kabra SK <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kabra%20SK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, et al.; ISCAP Study Group <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22ISCAP%20Study%20Group%22%5BCorporate%20Author%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. Br Med J 2004;328(7443):791.
  14. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pakistan%20Multicentre%20Amoxycillin%20Short%20Course%20Therapy%20(MASCOT)%20pneumonia%20study%20group%22%5BCorporate%20Author%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet <javascript:AL_get(this,%20'jour',%20'Lancet.');> 2002;14;360(9336):835-41.
  15. Cheung R <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cheung%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Sullens CM <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sullens%20CM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Seal D <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Seal%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, et al. The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community. Br J Clin Pharm 1988;26(4):391-98.
  16. Green J <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Green%20JL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Ray S <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ray%20SP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Charney E <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Charney%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>. Recurrence rate of streptococcal pharyngitis related to oral penicillin. J Pediatr <javascript:AL_get(this,%20'jour',%20'J%20Pediatr.');> 1969;75(2):292-94.
  17. Weis S <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Weis%20SE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Slocum P <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Slocum%20PC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Blais F <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Blais%20FX%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med <javascript:AL_get(this,%20'jour',%20'N%20Engl%20J%20Med.');> 1994;330(17):1179-84.
  18. Sethi AK <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sethi%20AK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Celentano DD <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Celentano%20DD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, Gange SJ <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gange%20SJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis <javascript:AL_get(this,%20'jour',%20'Clin%20Infect%20Dis.');> 2003;37(8):1112-18.
  19. Доступно на UPL: http://ru-romir.livejournal.com/105671.html#cutid1
  20. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Int Med 1990;150:1509-10.
  21. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995;49:321-27.
  22. Polla DL, Erdman AG, Robbins, et al. Microdevices in medicine. Ann Rev Biomed Engineer 2000;2:551-76.
  23. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
  24. Fallab-Stubi CL, Zellweger JP, Sauty A, et al. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998;2:525-30.
  25. Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proceedings of the Royal Society of London Series Biological Sciences 2000;267:835-43.
  26. Favre O, Delacretaz E, Badan, M, et al. Relationship between the prescriber's instructions and compliance with antibiotherapy in outpatients treated for an acute infectious disease. Clin Pharm 1997;37:175-78.
  27. Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgraduate Med 1992;68(3):49-58.
  28. Gil VF, Paya MA, Asensio MA, et al. Non-compliance of the treatment with antibiotics in non-severe acute infections. Med Clin 1999;112:31-33.
  29. Branthwaite A, Pechere JC. Pan-European survey of patients' attitudes to antibiotics and antibiotic use. Inter Med Resear 1996;24:229-38.
  30. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-99.
  31. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for outpatient management of infectious diseases. Inf Agents Dis 1994;3:266-73.
  32. Alvarez MP, Simon M, Sanchez S, et al. Pharmacovigilance study of azithromycin tablets (500 mg) in the treatment of adult patients with respiratory tract infections. Revista Espanola de Quimioter 2000;13:297-305.
  33. Kardas P, Ratajczyk-Pakalska E. Patient adherence in respiratory tract infections: ceftibuten versus other antibioticsт (PARTICULAR study). Polski Merkuriusz Lekarski 2001;10:445-49.
  34. Cook R, Zachariah J, Cree F, et al. Efficacy of twice-daily amoxycillin/clavulanate (Augmentin-Duo 400/57) in mild to moderate lower respiratory tract infections in children. British J Clin Pract 1996;50:125-28.
  35. Ramalle-Gomara E, Bermejo-Ascorbe R, Alonso Marin R, et al. Compliance with antibiotic treatment in non-hospitalized children. Atencion Primaria 1999;24:364-67.
  36. Lauvau D, Verbist L. An open, multicenter, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children. Pediatr Azithromycin Study Group. Intern Med Research 1997;25:285-95.
  37. Kardas P. Compliance to antibiotics in out-patients treated for respiratory infections. Pneum Alerg Polska 1999;67:398-408.
  38. Bergman A, Werner R. Failure of children to receive penicillin by mouth. New England J Med 1963;268:1334-38.
  39. Ellerbeck E, Khallaf N, Ansary K, et al. Caretaker compliance with different antibiotic formula tions for treatment of childhood pneumonia. J Tropical Pediatr 1995;41:102-08.
  40. Tomiki Y, Kanay Y, Danbara T, et al. Survey of outpatient waiting time. Juntendoigaku 2003;49:102-07.
  41. Kardas P, Devine S, Gollembesky A, et al. A systematic review and meta-analysis of misure of antibiotic therapies in the community. Int J Antimicrob 2005;26:106-13.
  42. Augenbraun M, Bachmann L, Wallace Т, et al. Compliance with doxycycline therapy in sexually transmitted diseases clinics. Sex Transm Dis 1998;25:12-13.
  43. Garey B, Gryan B. Antibiotic misuse in the community a contributor resistance? I Med J 2003;96:43-45.
  44. Kardas P. Comparison of patient compliance with once-dayly and twice-daily antibiotic regimens in respiratory tract infections: result of a randomized trial. J Antimicrob Chemother 2007;59:531-36.
  45. Guay DRP. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003;63:2169-84.
  46. Rudd P, Lenert L. Pharmacokinetics as an aid to optimising compliance with medications. Clin Pharmacokinet 1995;28:1-6.
  47. Ioannidis JP, Contopoulos-Ioannidis DG, Chew P, et al. <http://www.ncbi.nlm.nih.gov/pubmed/11679557?ordinalpos=26&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum> Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. J Antimicrob Chemother 2001;48(5):677-89.
  48. Meyler's Side Effects of Drugs. 13th. Dukes M.N.G. ed. Elsevier Science 1996;693-744.
  49. Pechere JC, Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. Antimicrob Chemother 2000;45:19-24.
  50. Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Рediat Infect Dis J 1996;15(Suppl. 9):30-37.
  51. Steele RW, Estrada B, Begue RE, et al. A double-blind taste comparison of pediatric antibiotic suspensions. Clin Pediatr 1997;36(4):193-99.
  52. Nikolaus Т, Kruse W, Bach M, et al. Elderly patients problems with medication. An in-hospital and follow-up study. Eur J Clin Pharm 1996;49:255-59.
  53. Janmeja AK, Das SK, Bhargava R, et al. Psychotherapy improves compliance with tuberculosis treatment. Respiration 2005;72(4):375-80.
  54. Lima J, Nazarian L, Charney E, et al Compliance with short-term antimicrobial therapy: some techniques that help. Pediatr 1976;57:383-86.
  55. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2239&mid=1085056570&magid=168&full=1

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2009

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах